BMJ Open

Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan

Abdul Sattar Shaikh, Ali Faisal Saleem, Shazia Samad Mohsin, Muhammad Matloob Alam, Mehnaz Atiq Ahmed

ABSTRACT

Objectives: To identify anthracycline-induced acute (within 1 month) and early-onset chronic progressive (within 1 year) cardiotoxicity in children younger than 16 years of age with childhood malignancies at a tertiary care centre of Pakistan.

Design: Prospective cohort study.

Setting: Aga Khan University, Karachi, Pakistan.

Participants: 110 children (aged 1 month–16 years).

Intervention: Anthracycline (doxorubicin and/or daunorubicin).

Outcome measurements: All children who received anthracycline as chemotherapy and three echocardiographic evaluations (baseline, 1 month and 1 year) between July 2010 and June 2012 were prospectively analyzed for cardiac dysfunction.

Statistical analysis including systolic and diastolic functions at baseline, 1 month and 1 year was carried out by repeated measures analysis of variance.

Results: Mean age was 74±44 months and 75 (68.2%) were males. Acute lymphoblastic leukaemia was seen in 70 (64%) patients. Doxorubicin alone was used in 59 (54%) and combination therapy was used in 35 (32%). A cumulative dose of anthracycline <300 mg/m² was used in 95 (86%). Fifteen (14%) children developed cardiac dysfunction within a month and 28 (25%) children within a year. Of these 10/15 (66.6%) and 12/28 (43%) had isolated systolic dysfunction, respectively, while 5/15 (33.3%) and 12/28 (43%) had isolated diastolic dysfunction. Seven (6.4%) patients expired due to cardiotoxicity. Eight of 59 (13.5%) and 16/28 (57%) had combined systolic and diastolic dysfunction, respectively, while 5/15 (33.3%) and 12/28 (43%) had isolated diastolic dysfunction. Five (6.6%) patients expired due to severe cardiac dysfunction. Eight of 59 (13.5%) children showed dose-related cardiotoxicity (p<0.001). Cardiotoxicity was also high when the combination of doxorubicin and daunorubicin was used (p=0.004).

Conclusions: Incidence of anthracycline-induced cardiotoxicity is high. Long-term follow-up is essential to diagnose its late manifestations.

INTRODUCTION

Anthracycline (doxorubicin, daunorubicin) are potent but cardiotoxic chemotherapeutic agents are essential for treating many childhood malignancies. Cardiotoxicity can be acute (within a month of initiation of therapy), early-onset chronic progressive (within a year after therapy) and late-onset chronic progressive (after a year of therapy).

Strengths and limitations of this study

- First prospective cohort study on Anthracycline induced cardiotoxicity from Pakistan.
- Repeated measures analysis of variance (r-ANOVA) analysis applied at three different intervals to detect acute and early onset cardiotoxicity.
- Single centre study. Poor follow-up was evident in our population.

PATIENTS AND METHODS

This prospective cohort study was performed during July 2010–June 2012 at the Aga Khan University Hospital, Karachi, Pakistan. It compared preanthracycline and postanthracycline...
echocardiographic evaluation in children aged 1 month–16 years with various childhood malignancies. Children with normal baseline echocardiography, who received anthracycline (daunorubicin and/or doxorubicin) as a part of their chemotherapy protocol and had the three desired echocardiographic evaluations (prechemotherapy 1-month and 1-year postschemotherapy), were enrolled in the study. Children were excluded; (1) if they were previously diagnosed with any structural heart disease or cardiomyopathy, (2) if they had succumbed to acute non-cardiac complications during their treatment course, (3) if they had a relapse of cancer. Of 190 patients enrolled in this study, 80 patients (42%) were excluded because of poor follow-up, treatment migration, self-treatment withdrawal. A total of 110 were available for final analysis (study flow diagram). Sociodemographic data were recorded and the type of cancer noted. A written informed consent (approved by the hospital’s ethical board) was obtained from parent or guardian by the principle investigator at the time of enrolment in the study. Anthracycline use, adverse events and possible outcome was informed to the parents/guardians by the treating paediatric oncologist. Demographic details, type of malignancy, type and cumulative dose of anthracycline and complications were noted. Anthracycline cumulative dose with respect to body surface area was calculated as mg/m². None of our patients received dexrazoxane during their management.

**Echocardiographic analysis**

GE vivid 7 Pro (General Electric Company, NYSE: GE, UK) or Philips IE33 (Philips Medical Systems, Andover, Massachusetts, USA) echocardiographic machines. Real-time images were obtained from standard parasternal, apical and subcostal projections. Transmitral inflow velocity pattern was recorded from the apical four-chamber view in accordance with the spectral Doppler techniques described elsewhere. M-mode tracings were taken from parasternal long axis view at the tips of mitral valve leaflets perpendicular to the LV endocardial surface and interventricular septum. Conscious sedation was used when indicated.

A baseline echocardiography was carried out in all patients as required in the management protocol. Echocardiographic assessment of systolic and diastolic LV function and PE was made. The mean of M-mode measurements from four cardiac cycles with the maximum diastolic diameters for each patient was used for analysis. LV cavity and posterior wall were measured in millimetre by the trailing edge-leading edge method. LV diastolic diameter and posterior wall diameter was measured at the point of maximum diastolic posterior deflection of the posterior wall. LV shortening fraction and ejection fraction were calculated by the formula

\[
\text{SF} = \frac{(\text{LVDD} - \text{LVDV})}{\text{LVDD}} \times 100 \text{(normal range 29–38%)}
\]

\[
\text{EF} = \frac{(\text{LVDV} - \text{LVSV})}{\text{LVDV}} \times 100 \text{(normal > 55%)}
\]

(SF, shortening fraction; EF, ejection fraction, LVDD, left ventricular diastolic diameter; LVDV, left ventricular systolic diameter; LVSD, left ventricular systolic volume; LVSV, left ventricular systolic volume).

Transmitral inflow velocity in early diastole (E) and during atrial contraction (A) was measured and E/A ratio calculated. Pulsed Tissue Doppler Imaging was used to record the velocity of myocardium during the cardiac cycle. Peak early diastolic myocardial velocity (E’) was measured at the lateral corner of the mitral annulus to evaluate diastolic dysfunction, E/E’ ratio assesses diastolic dysfunction. Myocardial performance index (MPI or Tei index) that incorporates systolic and diastolic time intervals and expresses global ventricular function was calculated using Doppler tracings from mitral and aortic flows. Isovolumic contraction time (IVCT), ejection time (ET) and isovolumic relaxation time (IVRT) were measured by standard techniques. In systolic dysfunction IVCT and IVRT will be prolonged while ET will be shortened, whereas in diastolic dysfunction IVRT will be prolonged. The higher the Tei index, the more abnormal would be the ventricular functions. Tei index was calculated as follows:

\[
\text{Tei index} = \frac{\text{IVCT} + \text{IVRT}}{\text{ET}} \text{(normal range 0.4 ± 0.09)}
\]

Echocardiographic evaluation for the acute and early-onset chronic cardiotoxicity was performed at three points in patient’s treatment course: baseline, 1 month and 1 year after chemotherapy.

The length of follow-up was measured from the first exposure to anthracycline. Preanthracycline echocardiographic functions were compared with 1-month postanthracycline echocardiography for acute cardiotoxicity and with 1-year postanthracycline echocardiography for the early-onset cardiotoxicity. Additional echocardiographic assessments were performed in case of cardiac failure and managed accordingly.

**Sample size**

Sample size estimation was performed by using repeated measures analysis of variance (r-ANOVA) design at three different intervals. To detect a mean difference of 3–4% units in ejection fraction, with SD of 8 from baseline to 1 month (acute toxicity), using 90% power, with 95% CI and 5% level of significance a maximum of 100 children were needed to detect the anthracycline-induced cardiotoxicity. Owing to an expected 10% dropout we inflate sample size to 110.

**Statistical analysis**

The statistical analysis was performed by using SPSS software package (V.20.0, SPSS). Continuous variables (age, weight, height, body surface area, haemodynamic parameters, cumulative anthracycline dose and echocardiographic evaluation parameters) were presented in the form of mean and SD. Categorical variables (gender, type of childhood cancer, type of anthracycline and...
discharge disposition) were presented in frequency and percentages. Statistical analysis across systolic and diastolic dysfunction at baseline, 1 month and 1 year were made by r-ANOVA using SPSS. A p value <0.05 was considered significant.

RESULTS
Among the 110 children enrolled 75 (68%) were males. Mean age was 74±44 months (median; 62 months). The demographic profile of the study population is shown in table 1. Haematological malignancies were predominant (n=82; 75%, acute lymphoblastic leukaemia (ALL) in 70 and acute myeloid leukaemia (AML) in 12). Five children had trisomy 21 (ALL in 3; AML in 2). Doxorubicin alone or in combination with daunorubicin was used in a majority of the children (n=94; 85%). Only 15 children received a high dose of anthracycline (cumulative dose >300 mg/m²). Follow-up echocardiography within 1 month revealed cardiac dysfunction in 15 (14%) children, while 28 (25%) developed myocardial dysfunction during their first year postanthracycline chemotherapy (figure 1).

Echocardiographic comparison of baseline myocardial function with that at 1 month and 1 year using r-ANOVA is shown in table 2. There was gradual and progressive deterioration in all myocardial functional parameters over time in children who received anthracycline. Children with haematological malignancies developed progressive cardiac dysfunction with time. Children with AML were found to have two times higher risk of developing myocardial dysfunction at 1 year compared with their baseline cardiac functions (table 3). Daunorubicin use was associated with the highest incidence of cardiac dysfunction at 1 year (10/16=63%) when compared with doxorubicin alone or in combination. High cumulative dose of daunorubicin, either alone or in combination with daunorubicin, had significant myocardial dysfunction (table 4).

DISCUSSION
Anthracycline use in childhood malignancies has remarkably improved survival rates, increasing from 30% in the 1960 to 70% in the present era.20 It is the key component in many treatment strategies, but its cardio-toxicity remains as an important concern. Incidence of

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Demographic features of children who received anthracycline for their chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients</td>
<td>n=110 (%)</td>
</tr>
<tr>
<td>Age (mean±SD)</td>
<td>74±44 months</td>
</tr>
<tr>
<td>Males</td>
<td>75 (68)</td>
</tr>
<tr>
<td>Body surface area (BSA)*</td>
<td>0.84±0.32</td>
</tr>
<tr>
<td>Type of malignancy</td>
<td></td>
</tr>
<tr>
<td>Haematological malignancies</td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td>70 (64)</td>
</tr>
<tr>
<td>AML</td>
<td>12 (11)</td>
</tr>
<tr>
<td>Non-haematological malignancies</td>
<td></td>
</tr>
<tr>
<td>Hodgkin+non-Hodgkin</td>
<td>19 (17)</td>
</tr>
<tr>
<td>Miscellaneous (Ewing sarcoma=4; Wilms tumour=5)</td>
<td>9 (8)</td>
</tr>
<tr>
<td>Type of anthracycline</td>
<td></td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>59 (53)</td>
</tr>
<tr>
<td>Combine doxorubicin and daunorubicin</td>
<td>35 (32)</td>
</tr>
<tr>
<td>Daunorubicin</td>
<td>16 (15)</td>
</tr>
<tr>
<td>Cumulative anthracycline dose (mg/m²)</td>
<td></td>
</tr>
<tr>
<td>&lt;100</td>
<td>40 (36)</td>
</tr>
<tr>
<td>100–300</td>
<td>55 (50)</td>
</tr>
<tr>
<td>&gt;300</td>
<td>15 (14)</td>
</tr>
<tr>
<td>Received radiation</td>
<td>24 (22)</td>
</tr>
<tr>
<td>Discharge disposition</td>
<td></td>
</tr>
<tr>
<td>Died</td>
<td>7 (6)</td>
</tr>
</tbody>
</table>

ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia.

Figure 1 Study flow diagram highlighting key features of study cohort.
Anthracycline-induced acute cardiotoxicity ranges between 3% and 21%, while late cardiotoxic effects vary between 0% and 57%. Anthracycline-induced acute cardiotoxicity in our study was 14%, which is a little high compared with the data published earlier. Cumulative doses greater than 300–400 mg/m² are associated with the greatest risk for cardiac injury. In our study, children receiving a cumulative dose >300 mg/m² had shown significant toxicity.

Anthracycline causes LV enlargement, both systolic and diastolic diameters increase, resulting in decreased fractioning shortening (FS) and EF. In our study baseline FS changed significantly after anthracyclines (p<0.001), which was similar to results published in the past. In our study a baseline LVEF of 69±4% reduced to 62.6±9.6% (p<0.001) at 1 year after completion of anthracycline therapy. Anthracycline-induced cardiac damage leads to deceased interventricular septal (IVS) and LV posterior wall thickness (PWT), thereby increasing after load and causing myocardial dysfunction. We also found differences in PWT and IVS preanthracycline and postanthracycline (p<0.001).

Systolic and diastolic myocardial velocities correlate well with systolic and diastolic ventricular functions. E, A and E’ velocities, E/A and E/E’ ratios, deceleration time (DT) and MPI (Tei index) are good indicators of diastolic dysfunction. Changes in EF occurs later in the treatment course. The Tei index is more sensitive as compared with EF and FS as it correlates well with invasive measurements and has been validated in the assessment of ventricular function, with higher values suggesting poor prognosis. It can diagnose myocardial dysfunction in children even after a low dose of anthracyclines. In our study, within a year after completion of therapy, there was a statically significant change in diastolic parameters like E velocity (p<0.001), A velocity (p<0.001), E/A ratio (p<0.001), E’ velocity (p<0.001) and E/E’ ratio (p<0.001). The Tei index and DT also showed significant changes (p<0.001). These findings were consistent with the medical literature.

Long-term follow-up studies have demonstrated cardiotoxicity in up to 70% of children treated with anthracycline. Younger patients are particularly susceptible to anthracycline-induced acute cardiotoxicity ranges between 3% and 21%, while late cardiotoxic effects vary between 0% and 57%. Anthracycline-induced acute cardiotoxicity in our study was 14%, which is a little high compared with the data published earlier. Generally, cumulative doses greater than 300–400 mg/m² are associated with the greatest risk for cardiac injury. In our study, children receiving a cumulative dose >300 mg/m² had shown significant toxicity.

### Table 2
Echocardiographic parameters comparing baseline readings with within a month and within a year after the start of anthracycline chemotherapy

<table>
<thead>
<tr>
<th>Echocardiographic parameters</th>
<th>Baseline readings</th>
<th>Within a month</th>
<th>Within a year</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EF (%)</td>
<td>69.9±4.3</td>
<td>67.3±5.3</td>
<td>62.6±9.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FS (%)</td>
<td>36.6±2.6</td>
<td>35.3±2.8</td>
<td>32.9±5.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PWT (mm)</td>
<td>6.7±1.3</td>
<td>5.8±1.1</td>
<td>5.4±1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IVS (mm)</td>
<td>5.9±0.2</td>
<td>5.4±1.1</td>
<td>4.9±1.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>34.5±5.6</td>
<td>35.8±5.4</td>
<td>37.3±5.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LVESD (mm)</td>
<td>22.0±4.2</td>
<td>23.4±4.4</td>
<td>25.3±5.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>E (cm/s)</td>
<td>93.7±9.2</td>
<td>86.8±10.3</td>
<td>85.1±11.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>A (cm/s)</td>
<td>58.9±6.5</td>
<td>63.5±7.5</td>
<td>64.6±9.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>1.6±1.8</td>
<td>1.38±0.21</td>
<td>1.3±.33</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>E’ (cm/s)</td>
<td>14.1±2.4</td>
<td>12.2±2.3</td>
<td>11.2±2.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>E/E’ ratio</td>
<td>6.7±1.05</td>
<td>7.17±1.1</td>
<td>8.1±2.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tei index (MPI)</td>
<td>0.3±0.5</td>
<td>0.4±0.5</td>
<td>0.4±0.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DT</td>
<td>164.3±15.3</td>
<td>171.6±19.8</td>
<td>174.7±28.9</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

A, peak flow velocity during atrial contraction; DT, E deceleration time; E, early diastolic mitral peak flow velocity; E’, peak early diastolic myocardial velocity; EF, ejection fraction; FS, fractioning shortening; IVS, interventricular wall thickness; LVEDD, left ventricular (LV) end diastolic diameter; LVESD, LV end systolic diameter; PWT, LV posterior wall thickness; Tei index, MPI=Myocardial performance index.

### Table 3
Relationship of anthracycline and cardiac dysfunction according to the type of malignancy

<table>
<thead>
<tr>
<th>Malignancy</th>
<th>Within a month (n (%))</th>
<th>Within a year (n (%))</th>
<th>p Value</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL (n=70)</td>
<td>3 (4)</td>
<td>12 (17)</td>
<td>0.004</td>
<td>1.3 (1.0 to 1.8)</td>
</tr>
<tr>
<td>AML (n=12)</td>
<td>5 (42)</td>
<td>9 (75)</td>
<td>0.091</td>
<td>2.3 (1.1 to 4.7)</td>
</tr>
<tr>
<td>Hodgkin lymphoma (n=12)</td>
<td>3 (25)</td>
<td>2 (17)</td>
<td>0.045</td>
<td>0.1 (0.1 to 0.6)</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma (n=7)</td>
<td>2 (28)</td>
<td>2 (28)</td>
<td>1.000</td>
<td>4.0 (0.1 to 136.9)</td>
</tr>
</tbody>
</table>

ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia.
anthracycline-induced cardiotoxicity. Incidence of cardiac dysfunction found more in males and those younger than 5 years in our study. Godoy et al.\(^3\) also found that children younger than 4 years developed more cardiotoxicity (p<0.01) in their study population.

Dysfunction is also related to the type of anthracycline used. Both doxorubicin and daunorubicin are cardiotoxic but doxorubicin is more cardiotoxic.\(^3\)\(^5\) Doxorubicin was used in 59/110 of our patients and 8/59 (13.5%) children showed cardiac dysfunction in the acute phase. Their cumulative dose of doxorubicin was significantly higher as compared with those without dysfunction, 279.4±184±.9 vs 103.6±69.4 mg/m\(^2\) (p=0.004). Cardiotoxicity was also high when a combination of doxorubicin and daunorubicin was used (p=0.004). In our study daunorubicin showed more toxicity in the early-onset chronic progressive phase.

PE can develop as a complication of anthracycline or radiation therapy, it may or may not be associated with cardiac dysfunction. It can be an early and alarming sign of cardiotoxicity suggestive of pericardial disease and sometimes leads to haemodynamic instability.\(^3\)\(^4\) Nineteen patients developed PE in this study.

Long-term cardiac follow-up is essential for early detection of cardiotoxicity because no dose of anthracycline is safe in children.\(^3\)\(^6\)\(^9\) Cardiotoxicity may progress years after discontinuation of therapy. Thirty years after anthracycline treatment, survivors have 15 times more chance of developing cardiac dysfunction than the general population and mortality from cardiac causes is eight times more.\(^3\)\(^5\) In our study, approximately 14% developed dysfunction within a month that increased to 25% at 1 year after completion of therapy. The full extent of the problem has yet to be addressed in many asymptomatic patients after the completion of treatment, emphasising the need for long-term follow-up.

In Pakistan multiple factors were related; non-compliance in follow-up with cardiologist and oncologist (in our study cardiac follow-up was seen in 58%). Common factors found were, parents understanding about disease, their educational status, financial constraints, minimal government and non-government agencies involvement and funding, remote area of residence far from treatment centres, paucity of treatment centres, poor counselling regarding long-term follow-up, lack of awareness among general practitioners regarding acute and chronic cardiac complications. This emphasises the need for long-term cardiac follow-up for better survival even in the asymptomatic patients.

A limitation of this study was that it involved a single centre. Owing to the lack of availability none of our children received cardioprotective agents such as dexrazoxane. Poor follow-up was evident in our study population which led to the exclusion of 80 patients. There was a high dropout rate; that is due to multiple factors aforementioned and also in study flow diagram.

### Table 4 Types of anthracycline used alone or in combination and their relation to cardiac dysfunction

<table>
<thead>
<tr>
<th>Anthracycline</th>
<th>Dysfunction</th>
<th>No dysfunction</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin (n=59)</td>
<td>Within a month: 8 (276±199), 51 (107±73)</td>
<td>Within a year: 9 (279±185), 50 (104±69)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Daunorubicin (n=16)</td>
<td>Within a month: 5 (315±114), 11 (273±93)</td>
<td>Within a year: 10 (310±85), 6 (247±114)</td>
<td>0.440</td>
</tr>
<tr>
<td>Combination (n=35)</td>
<td>Within a month: 2 (297±123), 33 (158±69)</td>
<td>Within a year: 9 (228±81), 26 (144±64)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

### CONCLUSION

The incidence of anthracycline-induced cardiac dysfunction is high. Risk factors include high cumulative dose, doxorubicin alone or in combination with daunorubicin. Regardless of the dose used, children treated with anthracycline require a long-term follow-up to detect late cardiotoxicity.

### Acknowledgements

The authors would like to acknowledge Dr Maha dev and Mr Cyrus Tariq for their help in data collection.

### Contributors

MAA acted as guarantor and senior investigator and reviewed the manuscript, observed every step and reviewed the ECHO data. AFS is the principal investigator, who generated the central idea, conducted the study and wrote the paper. AFS helped in conducting the study, study analysis and manuscript writing and reviewed the paper. SSM and MMA helped in data collection and helped in data entry and paper writing.

### Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

### Competing interests

AFS received research training support from the National Institute of Health’s Fogarty International Center (1 D43 TW007585-01).

### Ethics approval

Ethical Review Committee Aga Khan University (ERC # 2128 Ped ERC).

### Provenance and peer review

Not commissioned; externally peer reviewed.

### Data sharing statement

Extra data can be accessed by emailing to MAA: mehnaz.atiq@aku.edu.
REFERENCES

Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan

Abdul Sattar Shaikh, Ali Faisal Saleem, Shazia Samad Mohsin, Muhammad Matloob Alam and Mehnaz Atiq Ahmed

BMJ Open 2013 3:
doi: 10.1136/bmjopen-2013-003663

Updated information and services can be found at:
http://bmjopen.bmj.com/content/3/11/e003663

These include:

References
This article cites 35 articles, 9 of which you can access for free at:
http://bmjopen.bmj.com/content/3/11/e003663#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Cardiovascular medicine (738)
- Diagnostics (208)
- Oncology (393)
- Paediatrics (593)
- Pharmacology and therapeutics (426)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/